AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase I study titled ‘A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234.’ The study aims to assess how renal impairment affects the pharmacokinetics, safety, and tolerability of AZD6234, a drug administered as a single subcutaneous dose. This research is significant as it could provide insights into the drug’s performance in patients with varying degrees of renal function.
The intervention being tested is AZD6234, a drug administered in a single subcutaneous dose. It is intended to evaluate the drug’s behavior in the body, particularly in individuals with different levels of renal impairment compared to healthy controls.
The study design is interventional, non-randomized, and open-label, with a parallel-group model. It involves up to five cohorts, including those with end-stage renal disease, severe renal impairment, and healthy participants. The primary purpose is treatment-focused, with no masking involved.
The study began on February 24, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and potential market entry of AZD6234.
This study update could positively influence AstraZeneca’s stock performance by showcasing its commitment to expanding treatment options for patients with renal impairment. Investors might view this as a strategic move to capture a niche market, potentially impacting competitor dynamics in the renal treatment space.
The study is currently recruiting, with further details available on the ClinicalTrials portal.